Literature DB >> 8082669

Dose-response study on thyrotoxic patients undergoing positron emission tomography and radioiodine therapy.

M A Flower1, A al-Saadi, C L Harmer, V R McCready, R J Ott.   

Abstract

With the acknowledged problems associated with assessment of functioning thyroid mass and hence radiation dose, our policy had been to give 75 MBq iodine-131 at 6-monthly intervals to patients with Graves' disease until they became euthyroid. Since positron emission tomography (PET) has been available at this hospital, the radiation dose to the thyroid has been calculated with an accuracy of approximately 20%, the thyroid mass being determined from an iodine-124 PET scan. A dose-response study has been carried out on 65 patients who have received single or cumulative radiation doses of < 80 Gy. The results show that patients who receive a low radiation dose (< 20 Gy) at their first treatment have a high probability of remaining toxic at 12 months. In contrast, patients who receive higher radiation doses (> 40 Gy) at their first treatment have a high probability of control. The probability of becoming euthyroid increases more rapidly with increasing radiation dose than the probability of becoming hypothyroid. Following this dose-response study, a new treatment protocol has been introduced. A 124I PET tracer study prior to 131I therapy will be performed to enable a prescribed thyroid dose of 50 Gy to be delivered to patients with Graves' disease. Further 131I therapy will only be considered if patients are still toxic at 12 months.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8082669     DOI: 10.1007/bf00173041

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  12 in total

1.  Incidence of hypothyroidism and recurrences following I-131 treatment of hyperthyroidism.

Authors:  U BELING; J EINHORN
Journal:  Acta radiol       Date:  1961-10       Impact factor: 1.990

2.  RADIOACTIVE IODINE AS AN INDICATOR IN THYROID PHYSIOLOGY. V. THE USE OF RADIOACTIVE IODINE IN THE DIFFERENTIAL DIAGNOSIS OF TWO TYPES OF GRAVES' DISEASE.

Authors:  S Hertz; A Roberts
Journal:  J Clin Invest       Date:  1942-01       Impact factor: 14.808

3.  Thyroid imaging using positron emission tomography--a comparison with ultrasound imaging and conventional scintigraphy in thyrotoxicosis.

Authors:  M A Flower; A T Irvine; R J Ott; F Kabir; V R McCready; C L Harmer; H L Sharma; A G Smith
Journal:  Br J Radiol       Date:  1990-05       Impact factor: 3.039

Review 4.  Which therapy for Graves' hyperthyroidism in children?

Authors:  I R MacDougal
Journal:  Nucl Med Commun       Date:  1989-12       Impact factor: 1.690

5.  Low-dose radioiodine given six-monthly in Graves' disease.

Authors:  P J Hoskin; G S Spathis; V R McCready; D O Cosgrove; C L Harmer
Journal:  J R Soc Med       Date:  1985-11       Impact factor: 5.344

6.  Optimization of radioiodine therapy of thyrotoxicosis: what have we learned after 50 years?

Authors:  B Shapiro
Journal:  J Nucl Med       Date:  1993-10       Impact factor: 10.057

7.  Determination of thyroid volume by ultrasonic scanning.

Authors:  S N Rasmussen; L Hjorth
Journal:  J Clin Ultrasound       Date:  1974-06       Impact factor: 0.910

8.  Low-dose 131I in treatment of Graves' disease.

Authors:  C P Lowdell; H J Dobbs; G S Spathis; V R McCready; D O Cosgrove; C L Harmer
Journal:  J R Soc Med       Date:  1985-03       Impact factor: 5.344

9.  Measurement of radiation dose to the thyroid using positron emission tomography.

Authors:  R J Ott; V Batty; B S Webb; M A Flower; M O Leach; R Clack; P K Marsden; V R McCready; J E Bateman; H Sharma
Journal:  Br J Radiol       Date:  1987-03       Impact factor: 3.039

10.  Clinical outcome and costs of care in radioiodine treatment of hyperthyroidism.

Authors:  C A Hardisty; S J Jones; A J Hedley; D S Munro; P D Bewsher; R D Weir
Journal:  J R Coll Physicians Lond       Date:  1990-01
View more
  8 in total

Review 1.  The role of positron emission tomography within the spectrum of medical imaging.

Authors:  T Jones
Journal:  Eur J Nucl Med       Date:  1996-02

2.  Correction technique for cascade gammas in I-124 imaging on a fully-3D, Time-of-Flight PET Scanner.

Authors:  Suleman Surti; Ryan Scheuermann; Joel S Karp
Journal:  IEEE Trans Nucl Sci       Date:  2009-06       Impact factor: 1.679

3.  Combined PET/CT with iodine-124 in diagnosis of spread metastatic thyroid carcinoma: a case report.

Authors:  L S Freudenberg; G Antoch; R Görges; J Knust; R Pink; W Jentzen; J F Debatin; W Brandau; A Bockisch; J Stattaus
Journal:  Eur Radiol       Date:  2003-12       Impact factor: 5.315

4.  A mathematical model of optimized radioiodine-131 therapy of Graves' hyperthyroidism.

Authors:  Suhail AR Doi; Issa Loutfi; Kamal AS Al-Shoumer
Journal:  BMC Nucl Med       Date:  2001

5.  A Systematic Review and Meta-Analysis of the Relationship Between the Radiation Absorbed Dose to the Thyroid and Response in Patients Treated with Radioiodine for Graves' Disease.

Authors:  Jan Taprogge; Paul M D Gape; Lily Carnegie-Peake; Iain Murray; Jonathan I Gear; Francesca Leek; Steve L Hyer; Glenn D Flux
Journal:  Thyroid       Date:  2021-12       Impact factor: 6.568

6.  The diagnostic value of 124I-PET in patients with differentiated thyroid cancer.

Authors:  Ha T T Phan; Pieter L Jager; Anne M J Paans; John T M Plukker; M G G Sturkenboom; W J Sluiter; Bruce H R Wolffenbuttel; Rudi A J O Dierckx; Thera P Links
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-01-04       Impact factor: 9.236

7.  Comparison of clinical outcome after a fixed dose versus dosimetry-based radioiodine treatment of Graves' disease: Results of a randomized controlled trial in Indian population.

Authors:  Abhishek Kumar Jaiswal; Chandrasekhar Bal; Nishikant Avinash Damle; Sanjana Ballal; Ravinder Goswami; Smriti Hari; Praveen Kumar
Journal:  Indian J Endocrinol Metab       Date:  2014-09

8.  Dosimetry-based treatment for Graves' disease.

Authors:  Steve L Hyer; Brenda Pratt; Matthew Gray; Sarah Chittenden; Yong Du; Clive L Harmer; Glenn D Flux
Journal:  Nucl Med Commun       Date:  2018-06       Impact factor: 1.690

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.